Opioid Use Disorder (OUD)
Current BC and Canadian guidelines, algorithms, tools, prescribing references and patient resources for nurse practitioners.
Reviewed by Joe Grafe Due
Review overdue
This page was due for review on November 6, 2027. Check the linked sources for newer versions before relying on it.
Key Sources¶
BC Guidelines - Opioid Use Disorder: Diagnosis and Management in Primary Care (2018)
adults and youth in primary care; diagnosis, buprenorphine/naloxone as first-line opioid agonist treatment, induction and follow-up
BC Centre on Substance Use - A Guideline for the Clinical Management of Opioid Use Disorder (2023)
BC provincial guideline for the full continuum of care: oral and injectable opioid agonist treatment, antagonist treatment, withdrawal management, psychosocial treatment and harm reduction
CRISM - Management of Opioid Use Disorder: 2024 Update to the National Clinical Practice Guideline (CMAJ) (2024)
Canadian Research Initiative in Substance Matters; national synopsis on oral opioid agonist treatment, withdrawal management, psychosocial treatment and harm reduction; open access
Further Resources¶
- BC Guidelines - Opioid Use Disorder: Diagnosis and Management in Primary Care (2018) — adults and youth in primary care; diagnosis, buprenorphine/naloxone as first-line opioid agonist treatment, induction and follow-up
- BC Centre on Substance Use - A Guideline for the Clinical Management of Opioid Use Disorder (2023) · PDF — BC provincial guideline for the full continuum of care: oral and injectable opioid agonist treatment, antagonist treatment, withdrawal management, psychosocial treatment and harm reduction
Ontario Health quality standard - Opioid Use Disorder (Opioid Addiction): Care for People 16 Years of Age and Older (2018)
Ontario quality standard for opioid use disorder, with a clinician placemat and patient guide
- CAMH - Opioid Use and Opioid Use Disorder (Primary Care Addiction Toolkit) (2023) — Ontario primary care toolkit: screening, assessment and urine drug testing, pain management in at-risk patients, and OUD treatment with buprenorphine, methadone and slow-release oral morphine
- META:PHI - Toolkits — Ontario addiction medicine toolkits for primary care and emergency settings, from the Rapid Access Addiction Medicine network
BC Centre on Substance Use - Practice Updates and Clinical Bulletins
BCCSU updates that sit beside the 2023 guideline
- Opioid Use Disorder Practice Update (2022)
- Practice Update: Integrated, Interdisciplinary Model of Opioid Agonist Treatment (IIMOAT) (2022)
- Clinical Bulletin: Prescribed Alternatives Policy, Implications for Clinical Practice (2025) — witnessed prescribed alternatives from December 30, 2025
- Clinical Bulletin: Benzodiazepine-adulterated Opioids (2026)
- Extended-release Buprenorphine Bulletin (2026)
BC Centre on Substance Use - Guidance for Injectable Opioid Agonist Treatment for Opioid Use Disorder (2021)
BC guidance on injectable OAT
BC Centre on Substance Use - Treatment of Opioid Use Disorder During Pregnancy (2018)
guideline supplement; more on Pregnancy and Perinatal
BC Centre on Substance Use - Treatment of Opioid Use Disorder for Youth (2018)
guideline supplement for youth
Therapeutics Initiative - Therapeutics Letters on opioid use disorder
independent drug evaluation from UBC
CRISM - National Injectable Opioid Agonist Treatment for Opioid Use Disorder Clinical Guideline (2019)
Canadian Research Initiative in Substance Matters
CCSMH - Canadian Guidelines on Opioid Use Disorder Among Older Adults (2019)
Canadian Coalition for Seniors' Mental Health
Take-home naloxone programs in Canada: national best practice guidance (CMAJ) (2023)
CRISM; naloxone kits and overdose response training
AAFP - Common Questions About Buprenorphine Treatment for Opioid Use Disorder (2025)
International source: US guidance, not Canadian.
Algorithms and Pathways¶
- BC Centre on Substance Use - Buprenorphine/naloxone (Suboxone) To Go: Traditional Induction (2023) · PDF — step-by-step initiation guide
- BC Centre on Substance Use - Buprenorphine/naloxone (Suboxone) To Go: Low-dose (Micro-dosing) Induction (2023) · PDF
- BC Centre on Substance Use - LOUD in the ED: Emergency Department Buprenorphine/naloxone Induction Decision Support Tool (2020) · PDF — urgent and emergency care
No Pathways BC or Alberta pathway for opioid use disorder found.
Assessment Tools and Calculators¶
- BC Centre on Substance Use - Subjective Opiate Withdrawal Scale (SOWS) · PDF — patient-rated withdrawal scale
- BC Centre on Substance Use - DSM-5-TR Criteria for Opioid Use Disorder (2023) · PDF — diagnosis and severity
- BC Centre on Substance Use - Patient Assessment for Opioid Agonist Treatment · PDF — intake assessment form
- BC Centre on Substance Use - Urine Drug Testing in Patients Prescribed Opioid Agonist Treatment (2023) · PDF
- MDCalc: COWS Score for Opiate Withdrawal — Clinical Opiate Withdrawal Scale
- Clinical Opiate Withdrawal Scale form (BCCSU) — printable scale
Prescribing¶
- BCCNM - Nurse Practitioners: Prescribing for Opioid Use Disorder and/or Prescribed Alternatives (2026) · PDF — NP standard, limits and conditions; more on Prescribing Authority
- BC Centre on Substance Use - Physicians and Nurse Practitioners' Education and Training Pathway (POATSP) — Provincial Opioid Addiction Treatment Support Program training
- BC Centre on Substance Use - Methadone Chart: Formulation Information, Differences, and Preparation Details (2020) · PDF
BC PharmaCare - Opioid use disorder (last updated July 10, 2026) (2026)
full coverage of regular benefit OAT under Plans G, C, B and Z; OAT PINs; Special Authority and exceptional coverage
- OAT PINs and DINs
- Application for Exceptional Plan Z Coverage of OAT (HLTH 5829, rev. 2023/06/01) — for people not yet fully enrolled in MSP
- PharmaCare Special Authority Request: General (HLTH 5328) — 12 mg and 16 mg buprenorphine/naloxone, compounded methadone or a brand-name version
- RxFiles: Pain Book (Opioid Use Disorder chapter) — opioid agonist treatment comparison; some charts need an RxFiles subscription
Ontario Drug Benefit - Exceptional Access Program (EAP) (2026)
Ontario coverage for drugs not on the ODB Formulary; nurse practitioners submit requests through SADIE
Advice and Referral¶
- BC Centre on Substance Use - 24/7 Addiction Medicine Clinician Support Line — 778-945-7619; telephone advice from an addiction medicine specialist for BC physicians, NPs, nurses, pharmacists and midwives
- RACE - Rapid Access to Consultative Expertise — telephone and app advice from BC specialists for family physicians, nurse practitioners and midwives
- Pathways BC - Addiction Medicine · Addictions / Substance Use — login; specialists and clinics, with referral details
- Ontario eConsult (OTNhub) — specialist advice for Ontario physicians and nurse practitioners, usually without a patient referral
- BC Centre on Substance Use - OAT Clinics Accepting New Patients
Patient Resources¶
- HealthLink BC - Opioid Use Disorder
- BC Guidelines - Opioid Use Disorder: Resource Guide for Patients and Caregivers (2018) · PDF
- BC Guidelines - Buprenorphine/naloxone Home Induction Patient Handout (2018) · PDF
- BC Centre on Substance Use - Families and Caregivers — handbooks and help for families
- Toward the Heart (BCCDC) — BC harm reduction: take-home naloxone kits and a site finder
Also known as: OUD, opioid addiction, opioid dependence, OAT, opioid agonist treatment, opioid agonist therapy, buprenorphine, buprenorphine/naloxone, Suboxone, Sublocade, extended-release buprenorphine, methadone, Methadose, slow-release oral morphine, SROM, Kadian, iOAT, injectable OAT, fentanyl, opioid withdrawal, COWS, naloxone, overdose, toxic drug, prescribed alternatives, safer supply, BCCSU, CRISM, Plan Z, micro-dosing, low-dose initiation